SAN MATEO, Calif., May 4, 2021 /PRNewswire/ -- Vivace
Therapeutics, Inc., a small molecule discovery and development
company developing first-in-class therapies targeting the Hippo
pathway, announced today the completion of enrollment of the first
cohort of patients being treated with VT3989 in its Phase 1
clinical study. The Company anticipates enrolling the next higher
dose cohort in the second part of May.
The VT3989 Phase 1 study is now open at centers in both the US
(https://clinicaltrials.gov/ct2/show/NCT04665206) to evaluate the
safety, tolerability, PK and biological activity of VT3989 in
patients with refractory metastatic solid tumors, including
refractory pleural malignant mesothelioma. The study is currently
in dose escalation, to be followed by a dose expansion phase in
which patients with NF2 mutant tumors will be enrolled after
an optimal dose is determined. "To the best of our knowledge, we
are the first company to test a small molecule in the clinic
targeting this important pathway. Our preclinical work has shown
that tumors with NF2 mutations are quite sensitive to
VT3989, especially NF2-deficient mesothelioma," said
Leonard Post, Ph.D., Chief
Scientific Officer of Vivace Therapeutics.
"The Phase 1 clinical study is designed to test the
translatability of our preclinical observations in cancer patients
as quickly as possible. We are enrolling patients with a variety of
signaling abnormalities during dose escalation and will allow
NF2-mutated patients to backfill any previously cleared dose
cohorts. In addition, our study design allows for
intra-patient dose escalation so that patients who are tolerating
VT3989 at a given dose may increase to the highest well-tolerated
dose," said Andrew Dorr, M.D., Chief
Medical Officer of Vivace Therapeutics.
The Company has filed patent applications across a diverse set
of chemotypes, all of which inhibit palmitoylation of members of
the transcriptional enhanced associate domain (TEAD) protein
family. The latest publication from Vivace Therapeutics
titled "Small Molecule Inhibitors of TEAD Auto-palmitoylation
Selectively Inhibit Proliferation and Tumor Growth of
NF2-deficient Mesothelioma" in Molecule Cancer
presented some of the preclinical work done by the company.
About Vivace Therapeutics, Inc.
Vivace Therapeutics is a small molecule drug discovery and
development company focused on targeting the Hippo pathway. The
company is pursuing several first-in-class drug candidates to treat
human carcinomas of high unmet medical need. Based in San Francisco Bay Area, the company has raised
$70 million to date, and is funded by
leading biotechnology investors, including Canaan Partners, WuXi
Healthcare Ventures, Cenova Capital, Sequoia Capital China, Boxer
Capital and RA Capital Mangement. For more information, please
About the Hippo Pathway
The Hippo pathway is a key pathway used by cells to control
expression of a group of genes by regulating activity of
transcription factors YAP and TAZ. YAP and TAZ function in a
complex with partner proteins, the TEADs, which are the targets of
VT3989. A variety of human cancers depend on activation
of YAP and TAZ, which can occur by various mechanisms.
One mechanism by which YAP is activated in tumors is mutation of
the NF2 gene. NF2 mutation can occur in many
tumor types, including a high percentage of mesothelioma and
Sofie Qiao, Ph.D.
President and CEO
SOURCE Vivace Therapeutics, Inc.